{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T16:01:22Z","timestamp":1786377682283,"version":"build-2736575974"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T00:00:00Z","timestamp":1640217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Observational data suggest ceftaroline may be effective for methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection (BSI), but comparative data with standard of care are limited. This analysis compares the outcomes of MRSA BSI treated with ceftaroline or daptomycin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Multicenter, retrospective, observational cohort study of adult patients with MRSA BSI from 2010 to 2017. Patients treated with \u226572 hours of ceftaroline or daptomycin were included. Those clearing BSI before study drug and those with a pneumonia source were excluded. The primary outcome was composite treatment failure, defined as 30-day mortality, BSI duration \u22657 days on study drug, and 60-day MRSA BSI recurrence. Inverse probability of treatment weighted risk difference in composite failure between daptomycin and ceftaroline groups was computed and 15% noninferiority margin applied.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Two hundred seventy patients were included; 83 ceftaroline and 187 daptomycin. Ceftaroline was noninferior to daptomycin with respect to composite failure (39% daptomycin, 32.5% ceftaroline; weighted risk difference, 7.0% [95% confidence interval, \u20135.0% to 19.0%]). No differences between treatment groups was observed for 30-day mortality or other secondary efficacy outcomes. Creatine phosphokinase elevation was significantly more common among daptomycin patients (5.3% vs 0%, P = .034). Rash was significantly more common among ceftaroline patients (10.8 vs 1.1%, P = .001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>No difference in treatment failure or mortality was observed between MRSA BSI treated with ceftaroline or daptomycin. These data support future study of ceftaroline as a primary MRSA BSI treatment and current use of ceftaroline when an alternative to vancomycin and daptomycin is required.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofab606","type":"journal-article","created":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T05:56:43Z","timestamp":1640325403000},"source":"Crossref","is-referenced-by-count":23,"title":["Multicenter Cohort Study of Ceftaroline Versus Daptomycin for Treatment of Methicillin-Resistant <i>Staphylococcus aureus<\/i> Bloodstream Infection"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2595-1860","authenticated-orcid":false,"given":"Evan J","family":"Zasowski","sequence":"first","affiliation":[{"name":"Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA"},{"name":"Department of Clinical Sciences, Touro University California College of Pharmacy, Vallejo, California, USA"},{"name":"Department of Clinical Pharmacy, University of California, San Francisco School of Pharmacy, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9928-4714","authenticated-orcid":false,"given":"Trang D","family":"Trinh","sequence":"additional","affiliation":[{"name":"Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA"},{"name":"Department of Clinical Pharmacy, University of California, San Francisco School of Pharmacy, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6895-604X","authenticated-orcid":false,"given":"Kimberly C","family":"Claeys","sequence":"additional","affiliation":[{"name":"Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA"},{"name":"Department of Pharmacy Practice and Science, University of Maryland School of Pharmacy, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdalhamid M","family":"Lagnf","sequence":"additional","affiliation":[{"name":"Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahil","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth P","family":"Klinker","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Florida, Gainesville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5967-5211","authenticated-orcid":false,"given":"Michael P","family":"Veve","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Translational Science, College of Pharmacy, University of Tennessee Health Science Center, Knoxville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6833-9834","authenticated-orcid":false,"given":"Sandy\u00a0J","family":"Estrada","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Lee Health, Fort Myers, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5668-7564","authenticated-orcid":false,"given":"Scott T","family":"Johns","sequence":"additional","affiliation":[{"name":"Veterans Affairs San Diego Healthcare System, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7568-6735","authenticated-orcid":false,"given":"Adam J","family":"Sawyer","sequence":"additional","affiliation":[{"name":"Huntsville Hospital, Huntsville, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8028-3554","authenticated-orcid":false,"given":"Vanthida","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Midwestern University College of Pharmacy\u2013Glendale, Glendale, Arizona, USA"},{"name":"HonorHealth John C. Lincoln Medical Center, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandi","family":"LaFrance","sequence":"additional","affiliation":[{"name":"Our Lady of the Lake Regional Medical Center, Baton Rouge, Louisiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2252-5820","authenticated-orcid":false,"given":"Donald P","family":"Levine","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, School of Medicine, Wayne State University, Detroit, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2051-1732","authenticated-orcid":false,"given":"Keith S","family":"Kaye","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology, and Infectious Diseases, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9341-9964","authenticated-orcid":false,"given":"Susan\u00a0L","family":"Davis","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, Henry Ford Health System, Detroit, Michigan, USA"},{"name":"Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Rybak","sequence":"additional","affiliation":[{"name":"Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA"},{"name":"Department of Medicine, Division of Infectious Diseases, School of Medicine, Wayne State University, Detroit, Michigan, USA"},{"name":"Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA"},{"name":"Department of Pharmacy Services, Detroit Medical Center, Detroit, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,12,23]]},"reference":[{"key":"2022020902000540400_CIT0001","author":"Centers for Disease Control and Prevention."},{"key":"2022020902000540400_CIT0002","doi-asserted-by":"crossref","first-page":"ofaa010","DOI":"10.1093\/ofid\/ofaa010","article-title":"The effect of infectious diseases consultation on mortality in hospitalized patients with methicillin-resistant Staphylococcus aureus, Candida, and Pseudomonas bloodstream infections.","volume":"7","author":"Chesdachai","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2022020902000540400_CIT0003","doi-asserted-by":"crossref","first-page":"214","DOI":"10.15585\/mmwr.mm6809e1","article-title":"Vital signs: epidemiology and recent trends in methicillin-resistant and in methicillin-susceptible Staphylococcus aureus bloodstream infections\u2014United States.","volume":"68","author":"Kourtis","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2022020902000540400_CIT0004","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2022020902000540400_CIT0005","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/cid\/cir935","article-title":"The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis.","volume":"54","author":"van Hal","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2022020902000540400_CIT0006","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"key":"2022020902000540400_CIT0007","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/1471-2334-14-289","article-title":"A randomized phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study.","volume":"14","author":"Stryjewski","year":"2014","journal-title":"BMC Infect Dis"},{"key":"2022020902000540400_CIT0008","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/cid\/ciy279","article-title":"Dalbavancin as primary and sequential treatment for gram-positive infective endocarditis: 2-year experience at the General Hospital of Vienna.","volume":"67","author":"Tobudic","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2022020902000540400_CIT0009","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1086\/595686","article-title":"Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study.","volume":"48","author":"Wilcox","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2022020902000540400_CIT0010","doi-asserted-by":"crossref","first-page":"e02015-16","DOI":"10.1128\/AAC.02015-16","article-title":"Multicenter observational study of ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bloodstream infections.","volume":"61","author":"Zasowski","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020902000540400_CIT0011","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1093\/cid\/ciaa1572","article-title":"Comparative effectiveness of switching to daptomycin versus remaining on vancomycin among patients with methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections.","volume":"72","author":"Schweizer","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2022020902000540400_CIT0012","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/cid\/cir764","article-title":"Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study.","volume":"54","author":"Moore","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2022020902000540400_CIT0013","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/cid\/cit112","article-title":"Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration &gt;1\u00a0mg\/L: a matched cohort study.","volume":"56","author":"Murray","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2022020902000540400_CIT0014","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1128\/JCM.00660-07","article-title":"Evaluation of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin.","volume":"46","author":"Sakoulas","year":"2008","journal-title":"J Clin Microbiol"},{"key":"2022020902000540400_CIT0015","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10096-007-0455-5","article-title":"High rate of decreasing daptomycin susceptibility during the treatment of persistent Staphylococcus aureus bacteremia.","volume":"27","author":"Sharma","year":"2008","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2022020902000540400_CIT0016","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/jac\/dkr066","article-title":"Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure.","volume":"66","author":"Kelley","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2022020902000540400_CIT0017","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1093\/jac\/dkt396","article-title":"Emergence of resistance to daptomycin in a cohort of patients with methicillin-resistant Staphylococcus aureus persistent bacteraemia treated with daptomycin.","volume":"69","author":"Gasch","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2022020902000540400_CIT0018","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.1128\/AAC.00307-09","article-title":"Correlation between vancomycin MIC values and those of other agents against gram-positive bacteria among patients with bloodstream infections caused by methicillin-resistant Staphylococcus aureus.","volume":"53","author":"Patel","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020902000540400_CIT0019","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1086\/430352","article-title":"Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact.","volume":"191","author":"Silverman","year":"2005","journal-title":"J Infect Dis"},{"key":"2022020902000540400_CIT0020","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1128\/AAC.00484-13","article-title":"Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011.","volume":"57","author":"Sader","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020902000540400_CIT0021","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ajic.2008.03.002","article-title":"CDC\/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting.","volume":"36","author":"Horan","year":"2008","journal-title":"Am J Infect Control"},{"key":"2022020902000540400_CIT0022","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support.","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2022020902000540400_CIT0023","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2022020902000540400_CIT0024","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","article-title":"APACHE II: a severity of disease classification system.","volume":"13","author":"Knaus","year":"1985","journal-title":"Crit Care Med"},{"key":"2022020902000540400_CIT0025","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1086\/652767","article-title":"Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis.","volume":"50","author":"Bhavnani","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2022020902000540400_CIT0026","author":"National Cancer Institute Cancer Therapy Evaluation Program.","year":"1999"},{"key":"2022020902000540400_CIT0027","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/phar.1220","article-title":"Implementation of an antimicrobial stewardship pathway with daptomycin for optimal treatment of methicillin-resistant Staphylococcus aureus bacteremia.","volume":"33","author":"Kullar","year":"2013","journal-title":"Pharmacotherapy"},{"key":"2022020902000540400_CIT0028","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1128\/AAC.02371-13","article-title":"Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy.","volume":"58","author":"Casapao","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020902000540400_CIT0029","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1093\/aje\/kwj149","article-title":"Variable selection for propensity score models.","volume":"163","author":"Brookhart","year":"2006","journal-title":"Am J Epidemiol"},{"key":"2022020902000540400_CIT0030","doi-asserted-by":"crossref","first-page":"e01902-17","DOI":"10.1128\/AAC.01902-17","article-title":"Host-pathogen-treatment triad: host factors matter most in methicillin-resistant Staphylococcus aureus bacteremia outcomes.","volume":"62","author":"Guillamet","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020902000540400_CIT0031","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/01.md.0000091184.93122.09","article-title":"Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study.","volume":"82","author":"Chang","year":"2003","journal-title":"Medicine (Baltim)"},{"key":"2022020902000540400_CIT0032","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.diagmicrobio.2006.01.021","article-title":"Risk factors for recurrence in patients with Staphylococcus aureus infections complicated by bacteremia.","volume":"55","author":"Kreisel","year":"2006","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2022020902000540400_CIT0033","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jinf.2013.10.015","article-title":"Staphylococcus aureus bloodstream infection: a pooled analysis of five prospective, observational studies.","volume":"68","author":"Kaasch","year":"2014","journal-title":"J Infect"},{"key":"2022020902000540400_CIT0034","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1086\/375057","article-title":"Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia.","volume":"36","author":"Lodise","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2022020902000540400_CIT0035","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","article-title":"Marginal structural models and causal inference in epidemiology.","volume":"11","author":"Robins","year":"2000","journal-title":"Epidemiology"},{"key":"2022020902000540400_CIT0036","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/bimj.200810488","article-title":"Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations.","volume":"51","author":"Austin","year":"2009","journal-title":"Biom J"},{"key":"2022020902000540400_CIT0037","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/pds.1674","article-title":"Assessing balance in measured baseline covariates when using many-to-one matching on the propensity-score.","volume":"17","author":"Austin","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2022020902000540400_CIT0038","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/cid\/ciu398","article-title":"Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough?","volume":"59","author":"Lodise","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2022020902000540400_CIT0039","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/cid\/cit582","article-title":"Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia.","volume":"57","author":"Falcone","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2022020902000540400_CIT0040","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/phar.2070","article-title":"Association of higher daptomycin dose (7\u00a0mg\/kg or greater) with improved survival in patients with methicillin-resistant Staphylococcus aureus bacteremia.","volume":"38","author":"Timbrook","year":"2018","journal-title":"Pharmacotherapy"},{"key":"2022020902000540400_CIT0041","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ijantimicag.2014.12.023","article-title":"Pharmacokinetic\/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function.","volume":"45","author":"Canut","year":"2015","journal-title":"Int J Antimicrob Agents"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofab606\/41909796\/ofab606.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/3\/ofab606\/42418376\/ofab606.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/3\/ofab606\/42418376\/ofab606.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T02:27:40Z","timestamp":1644373660000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofab606\/6481735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,23]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofab606","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3,1]]},"published":{"date-parts":[[2021,12,23]]},"article-number":"ofab606"}}